Xarelto, also known as rivaroxaban, is a prescription drug developed by Bayer and Johnson & Johnson. The drug is an oral medication originally approved by the FDA to reduce the risk of dangerous blood clots in patients who had undergone knee or hip replacement surgery. The drug is also used to reduce the risk of stroke in patients with atrial fibrillation, and treat pulmonary embolism and deep vein thrombosis in different individuals.
Compared to other prescription anticoagulants, Xarelto does not require frequent check ups with a medical professional. It is taken orally in a uniform dose, while similar drugs on the market are prescribed in specific doses for patients. Xarelto is known to cause more problems in patients than other anticoagulants.
Harmful Side Effects
The side effects of Xarelto use can be fatal. One of the most severe side effects of the drug is uncontrolled bleeding. Unlike other anticoagulants, Xarelto has no known antidote for the excessive bleeding caused by the medication, and many patients have been hospitalized as result. In the worst cases, the uncontrolled bleeding results in the Xarelto user’s death.
Along with severe gastrointestinal and other hemorrhaging, the other serious side effects associated with Xarelto use include the very things it works to treat:
- Pulmonary Embolism
- Deep Vein Thrombosis
If you or a loved one have experienced any of the adverse side effects mentioned above, you might be eligible to file a lawsuit against the drug’s manufacturers, Bayer and Johnson & Johnson.
Your Legal Options
Many of those who have suffered from uncontrollable and irreversible bleeding or other side effects due to Xarelto use have filed lawsuits to be compensated for medical bills, injuries, and emotional trauma.
Our attorneys are currently evaluating cases related to Xarelto. If you took Xarelto, please contact us through this simple form or our toll-free number, 800-598-0314. You might be entitled to compensation for medical bills associated with your condition, pain and suffering, and more.